MMF Shows Promise in Juvenile Scleroderma - Top_Thought_Leaders - MDSpire

MMF Shows Promise in Juvenile Scleroderma

Mycophenolate mofetil demonstrated comparable disease control with fewer adverse effects.

  • By

  • Kathryn Wighton

  • February 2, 2026

  • 3 min

Share

Top Thought Leaders in Pathology

Brief introduction explaining scope and methodology.

Original Source(s)

MMF Shows Promise in Juvenile Scleroderma

  • by Kathryn Wighton

  • February 2, 2026

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

Lymphocyte transformation test in pediatric drug hypersensitivity: case series report from a tertiary care hospital